WITTMAN VANESSA AMES sold $806K of OSCR

WITTMAN VANESSA AMES sold 25,000 shares of Oscar Health, Inc. (OSCR) at $32.24 ($0.81M total) on 2026-09-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · WITTMAN VANESSA AMES
Published Sep 22, 2026, 8:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 8:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OSCR
Neutral
medium confidence
Mentioned
$OSCR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OSCRNeutralLow
01

Why it matters

The disclosed sale adds a data point for monitoring insider activity but does not constitute a material corporate event.

02

Market read

Provides a fresh insider transaction for Oscar Health, useful for short‑term monitoring but limited trading significance.

03

What to watch

The director retains a sizable stake (112,121 shares) and the sale was pre‑arranged, reducing informational asymmetry.

Relevance 4/10Novelty 5/10Timing: filed today

Background

SEC Form 4 filings disclose insider transactions and are primary sources for new corporate ownership changes.

Company-level read

Ticker impact

$OSCRNeutralMedium confidence
Context

Director Vanessa Wittman Ames sold 25,000 shares of Oscar Health for $806K via a 10b5-1 plan.

Expected impact

Potential slight downward pressure, likely within normal volatility range.

Evidence & confidence

A $806K sale represents ~0.7% of the insider's post‑transaction holdings and is a routine 10b5‑1 execution.

Market effects

Minimal impact on the health‑tech sector; insider sales are common and not sector‑wide signals.

No notable regional effect; the filing is specific to Oscar Health.

Limited global relevance; only relevant to investors tracking Oscar Health.

Counterpoint

The sale could be a routine liquidity event rather than a lack of confidence, so price impact may be negligible.

Key entities

  • Oscar Health, Inc.

    US‑listed health‑tech insurer (ticker OSCR).

  • Vanessa Wittman Ames

    Director of Oscar Health executing a 10b5‑1 sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$OSCRHighAI 8/10

What Oscar Health (OSCR) Said on Its Q3 Earnings Call

Oscar Health (OSCR) reported Q3 improvements in medical loss ratio (84%) and SG&A expense ratio (14%). The company raised its 2026 outlook, expecting $850M-$950M in earnings from operations and $19B-$19.3B in revenue. Membership grew 27% YoY to 2.7M, but is expected to decline to 2.5M by year-end due to disenrollments. Oscar plans to expand its footprint and products for 2027.

$OSCRMed

Oscar Health Inc (OSCR) Q3 2026 Earnings Call Highlights: Record Profitability, Raised

Oscar Health (OSCR) reported Q3 2026 earnings with record profitability and raised guidance. Membership declined due to CMS reviews, with more disenrollments expected. Q4 SG&A expenses are projected to rise due to seasonal spending. CEO Mark Bertolini and CFO Richard Blackley discussed market share gains, utilization trends, and CMS program integrity initiatives. The company anticipates stable membership and market growth despite competitive pressures and regulatory uncertainties.

$OSCRHighAI 8/10

Oscar Health (OSCR) Q3 2026 Earnings Call Transcript

Oscar Health (OSCR) reported Q3 2026 revenue of $5.1B, up 70% YoY, with membership at 2.7M, up 27% YoY. Net income was $167.3M, reversing a prior-year loss. The company raised full-year guidance for revenue, earnings, and adjusted EBITDA. Management highlighted expansion into new markets, product launches, and operational efficiencies.

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.